N. Ibrahim

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

J. Stec, M. Ayers, K. Hess, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction

V. Valero, S. Krishnamurthy, N. Ueno, 2016, PloS one.

Defining prognosis for women with breast cancer and CNS metastases by HER2 status.

K. Aldape, G. Hortobagyi, N. Ibrahim, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer.

G. Hortobagyi, A. Buzdar, F. Holmes, 1997, Seminars in oncology.

Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect.

G. Hortobagyi, V. Valero, D. Booser, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients.

L. Pusztai, R. Rouzier, N. Ibrahim, 2009, Journal of Clinical Oncology.

MicroRNA-21 and microRNA-34a in Relation to other biological markers in Egyptian Breast Cancer Female Patients

N. Ibrahim, Fatma H. El-Rashidy, N. Shaban, 2017 .

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

G. Hortobagyi, V. Valero, N. Ibrahim, 2013, Clinical & Experimental Metastasis.

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.

G. Mills, G. Hortobagyi, L. Pusztai, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.

G. Hortobagyi, S. Singletary, F. Ames, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy.

S. Singletary, B. Fornage, B. Edeiken, 1999, Radiology.